LadeRx
CompanyUnited States
LadeRx develops 2 assets, the furthest in phase 1 (Ascor L 500 in pharmacokinetic). Mostly small molecule acting on Oxidative stress and ROS signalling; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
2Essential antioxidant and enzyme cofactor involved in collagen synthesis and cellular redox defense
Phase 1, Small molecule, Oxidative stress and ROS signalling, pharmacokinetic
Formulation of ascorbic acid acting as an antioxidant or pro-oxidant.
Phase 1, Small molecule, Oxidative stress and ROS signalling
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Similar companies6